Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Ulocuplumab






●Italiano
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Ulocuplumab

Monoclonal antibody

Type

Whole antibody

Source

Human

Target

C-X-C chemokine receptor type 4

Clinical data

Other names

MDX-1338

ATC code

  • none

Identifiers

CAS Number

ChemSpider

  • none

UNII

Chemical and physical data

Formula

C6486H9960N1720O2046S46

Molar mass

146243.78 g·mol−1

Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]

This drug was developed by Bristol-Myers Squibb.

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  • ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.


    • Immune system

    Human

  • Adalimumab#
  • Anifrolumab
  • Atorolimumab
  • Avelumab
  • Avdoralimab
  • Belimumab
  • Bleselumab
  • Brodalumab
  • Camidanlumab tesirine
  • Carlumab
  • Cemiplimab
  • Dupilumab
  • Eldelumab
  • Emapalumab
  • Fresolimumab
  • Golimumab
  • Ianalumab†
  • Lanadelumab
  • Lenzilumab
  • Lerdelimumab
  • Lirentelimab
  • Lirilumab
  • Mavrilimumab
  • Metelimumab
  • Morolimumab
  • Namilumab
  • Oleclumab
  • Oxelumab§
  • Pamrevlumab
  • Placulumab
  • Relatlimab†
  • Sarilumab
  • Sifalimumab
  • Tabalumab
  • Tezepelumab
  • Ulocuplumab
  • Varlilumab

    • Mouse

  • Elsilimomab
  • Faralimomab
  • Gavilimomab
  • Inolimomab
  • Maslimomab
  • Nerelimomab
  • Odulimomab
  • Telimomab aritox
  • Vepalimomab
  • Zolimomab aritox

    • Chimeric

  • Basiliximab
  • Clenoliximab
  • Galiximab
  • Gomiliximab
  • Infliximab
  • Keliximab
  • Lumiliximab
  • Priliximab
  • Teneliximab
  • Vapaliximab

    • Humanized

  • Aselizumab
  • Atezolizumab
  • Benralizumab
  • Camrelizumab†
  • Cedelizumab
  • Certolizumab pegol
  • Crizanlizumab
  • Daclizumab
  • Eculizumab
  • Efalizumab‡
  • Epratuzumab
  • Erlizumab
  • Etrolizumab†
  • Fontolizumab
  • Frexalimab†
  • Inebilizumab
  • Itolizumab
  • Lampalizumab†
  • Letolizumab
  • Ligelizumab†
  • Lulizumab pegol
  • Mepolizumab
  • Mogamulizumab
  • Natalizumab
  • Ocrelizumab
  • Omalizumab
  • Ozoralizumab
  • Pascolizumab
  • Pateclizumab
  • Pembrolizumab
  • Pexelizumab
  • Pidilizumab
  • Plozalizumab
  • PRO 140†
  • Quilizumab
  • Ravulizumab
  • Reslizumab
  • Retifanlimab
  • Rontalizumab
  • Rovelizumab
  • Ruplizumab
  • Samalizumab
  • Satralizumab
  • Siplizumab
  • Spartalizumab†
  • Talizumab
  • Teclistamab
  • Teplizumab
  • Tislelizumab
  • Tocilizumab
  • Toralizumab
  • Tregalizumab
  • Vatelizumab
  • Vedolizumab
  • Visilizumab
  • Vobarilizumab
  • TGN1412§

    • Immune activation: Dostarlimab
    Other: Ibalizumab

    Chimeric + humanized

  • Rozanolixizumab
  • Sutimlimab

    • Interleukin

    Human

  • Brazikumab
  • Briakinumab
  • Canakinumab
  • Fezakinumab
  • Fletikumab
  • Guselkumab
  • Secukinumab
  • Sirukumab
  • Tralokinumab
  • Ustekinumab

    • Humanized

  • Bimekizumab
  • Clazakizumab
  • Gevokizumab
  • Ixekizumab
  • Mirikizumab†
  • Lebrikizumab
  • Olokizumab†
  • Perakizumab
  • Risankizumab
  • Spesolimab
  • Tildrakizumab

    • Veterinary

    Inflammatory lesions

    Mouse

  • Fanolesomab‡
  • Lemalesomab
  • Sulesomab

  • ‡Withdrawn from market
  • Clinical trials:
  • §Never to phase III

    • CC

    CCR1

  • CCL5 (RANTES)
  • CCL6
  • CCL9 (CCL10)
  • CCL14
  • CCL15
  • CCL16
  • CCL23

    • CCR2

  • CCL8
  • CCL12
  • CCL16

    • CCR3

  • CCL7
  • CCL11
  • CCL13
  • CCL15
  • CCL18
  • CCL24
  • CCL26
  • CCL28

    • CCR4

  • CCL5 (RANTES)
  • CCL17
  • CCL22

    • CCR5

  • CCL4 (MIP-1β)
  • CCL5 (RANTES)
  • CCL8
  • CCL11
  • CCL13
  • CCL14
  • CCL16

    • CCR6

    CCR7

  • CCL21

    • CCR8

  • CCL16

    • CCR9

    CCR10

  • CCL28

    • CCR11

  • CCL21
  • CCL25

    • Ungrouped

  • Carlumab (against CCL2)

    • CXC

    CXCR1
    (IL-8Rα)

  • Emoctakin
  • Interleukin-8 (CXCL8, GCP-1)

    • CXCR2
    (IL-8Rβ)

  • CXCL2
  • CXCL3
  • CXCL5
  • CXCL6
  • CXCL7
  • Emoctakin
  • Garnocestim
  • Interleukin-8 (CXCL8, GCP-1)

    • CXCR3

  • CXCL9 (MIG)
  • CXCL10 (IP-10)
  • CXCL11 (I-TAC)
  • Iroplact

    • CXCR4

  • SDF-1 (CXCL12)
  • Ubiquitin

    • CXCR5

    CXCR6

    CXCR7

  • SDF-1 (CXCL12)

    • C (XC)

    XCR1

  • Lymphotactin-β (XCL2)

    • CX3C

    CX3CR1

    Others

    CCBP2

    CMKLR1

  • Resolvin E1


    • Stub icon

    This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Ulocuplumab&oldid=1160196512"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Monoclonal antibodies
     ●Monoclonal antibody stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Chemicals that do not have a ChemSpider ID assigned
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●Drugs that are a monoclonal antibody
     ●All stub articles
      


    ●This page was last edited on 15 June 2023, at 00:18 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki